Pirtobrutinib induced a response in six of the eight patients with WM who were progressing on a covalent BTK inhibitor, without evidence of arrhythmia, a well‐known adverse event associated with covalent BTK inhibitors. The gene discussed is BTK; the disease is cardiac arrhythmia.